Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 71 citing articles:

The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study
Veronica Mollica, Alessandro Rizzo, Andrea Marchetti, et al.
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 8, pp. 5039-5049
Closed Access | Times Cited: 124
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study
Alessandro Rizzo, Veronica Mollica, Valentina Tateo, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 6, pp. 1381-1394
Closed Access | Times Cited: 112
Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy
Stefanie Bärthel, Chiara Falcomatà, Roland Rad, et al.
Nature Cancer (2023) Vol. 4, Iss. 4, pp. 454-467
Open Access | Times Cited: 48
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort
Julien Taı̈eb, Lina Sayah, Kathrin Heinrich, et al.
European Journal of Cancer (2023) Vol. 188, pp. 90-97
Closed Access | Times Cited: 44
Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept
Wenyu Luo, Ti Wen, Xiujuan Qu
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 24
Therapeutic Monoclonal Antibodies against Cancer: Present and Future
Marisa Delgado, José A. García‐Sanz
Cells (2023) Vol. 12, Iss. 24, pp. 2837-2837
Open Access | Times Cited: 31
Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer
Alexander G. Raufi, Michael May, Matthew J. Hadfield, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 4238-4238
Open Access | Times Cited: 30
Consensus, debate, and prospective on pancreatic cancer treatments
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 11
Barriers and opportunities in pancreatic cancer immunotherapy
Yixin Ju, Dongzhi Xu, Miao-Miao Liao, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 9
Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review
Maryam Noori, Farideh Jafari‐Raddani, Zeinab Davoodi‐Moghaddam, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 8
Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma
Ann Mary Joseph, Ahmad Al Aiyan, Basel K. al-Ramadi, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy
Marc Hilmi, Matthieu Delaye, Milena Muzzolini, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 12, pp. 1129-1142
Closed Access | Times Cited: 21
Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights
Rita Balsano, Valentina Zanuso, Angelo Pirozzi, et al.
Current Oncology (2023) Vol. 30, Iss. 4, pp. 3871-3885
Open Access | Times Cited: 18
Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1
Max M. Wattenberg, Heather Coho, Veronica M. Herrera, et al.
Science Immunology (2023) Vol. 8, Iss. 89
Open Access | Times Cited: 18
Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application
Rui Zheng, Xiaobin Liu, Yufu Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Small molecular inhibitors for KRAS-mutant cancers
Xuan Wu, Wenping Song, Cheng Cheng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
Md Sazzad Hassan, Niranjan Awasthi, Saisantosh Ponna, et al.
Biomedicines (2023) Vol. 11, Iss. 7, pp. 2000-2000
Open Access | Times Cited: 14
Exploring the Therapeutic Potential of Focal Adhesion Kinase Inhibition in Overcoming Chemoresistance in Pancreatic Ductal Adenocarcinoma
Fabio Scianò, Francesca Terrana, Camilla Pecoraro, et al.
Future Medicinal Chemistry (2024) Vol. 16, Iss. 3, pp. 271-289
Closed Access | Times Cited: 5
High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study
Lei Huang, Yao Lv, Shasha Guan, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Biodistribution and therapeutic efficacy of a gold nanoparticle-based targeted drug delivery system against pancreatic cancer
Chandra Kumar Elechalawar, Suresh Kumar Gulla, Ram Vinod Roy, et al.
Cancer Letters (2024) Vol. 589, pp. 216810-216810
Closed Access | Times Cited: 5
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors
Benjamin Garmezy, Mitesh J. Borad, Rastilav Bahleda, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 4, pp. 1165-1173
Open Access | Times Cited: 5
The double life of a chemotherapy drug: Immunomodulatory functions of gemcitabine in cancer
Alaina C. Larson, Kenadie R. Doty, Joyce C. Solheim
Cancer Medicine (2024) Vol. 13, Iss. 10
Open Access | Times Cited: 5
The Current Landscape of Clinical Trials for Immunotherapy in Pancreatic Cancer: A State-of-the-Art Review
Zouina Sarfraz, Azza Sarfraz, Muhammad Farooq, et al.
Journal of Gastrointestinal Cancer (2024) Vol. 55, Iss. 3, pp. 1026-1057
Closed Access | Times Cited: 5
Impact of anti-PD1 immunotherapy and circulating tumor cells on progression-free survival in surgical pancreatic adenocarcinoma: a retrospective cohort study
Yonggang He, Yinan Zhu, Zhenzhen Xiao, et al.
Expert Review of Clinical Immunology (2025), pp. 1-10
Closed Access
The multi-faceted roles of cancer-associated fibroblasts in pancreatic cancer
John Y. Kwon, Renzo E. Vera, Martín E. Fernández-Zapico
Cellular Signalling (2025) Vol. 127, pp. 111584-111584
Open Access
Page 1 - Next Page

Scroll to top